BiomX Inc. (PHGE) Cash Flow Statement

The extreme volatility in the OCF/NI ratio indicates that net income is an unreliable proxy for the company's actual cash position due to non-cash items like warrant revaluations. Investors should monitor the cash flow statement directly, as the recurring negative operating cash flow confirms that the business remains in a state of continuous capital depletion.

The absence of positive free cash flow is expected for a clinical-stage entity, yet the magnitude of these outflows relative to the remaining cash balance warrants significant concern. This trajectory suggests that the company is highly sensitive to capital market conditions, which may limit its ability to complete critical Phase 2b trials.

These fluctuations in working capital appear to be driven by the timing of clinical research organization payments and other R&D-related liabilities. The lack of a stable working capital cycle suggests that management has limited control over cash timing, further exacerbating the risks associated with the company's tight liquidity position.

The decision to prioritize inorganic growth through acquisition during a period of extreme cash scarcity suggests that management views pipeline expansion as the only viable path to long-term value creation. However, this strategy places additional pressure on the already limited cash runway, necessitating a careful evaluation of the acquisition's potential to accelerate clinical milestones.